Genotoxicity testing: Moving beyond qualitative "screen and bin" approach towards characterization of dose-response and thresholds

Environmental and Molecular Mutagenesis

Volumn 51, Issue 8-9, 2010, Pages 792-799

  Pottenger, Lynn H ^a   Gollapudi, B Bhaskar ^a  

^a DOW CHEMICAL COMPANY   (United States)

Author keywords

Dose response; Genotoxicity; Mode of action; Mutagenicity; Thresholds

Indexed keywords

BIOLOGICAL MARKER; MUTAGENIC AGENT;

DOSE RESPONSE; GENETIC TOXICOLOGY; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MUTAGENIC ACTIVITY; REVIEW; RISK ASSESSMENT; STATISTICAL MODEL; TOXICITY TESTING; HEALTH CARE ORGANIZATION; HISTORY; MUTAGEN TESTING;

DOSE-RESPONSE RELATIONSHIP, DRUG; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; MUTAGENICITY TESTS; MUTAGENS; SOCIETIES, SCIENTIFIC;

EID: 78349237710     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20612     Document Type: Review

References (38)

1. Arlett CF, Smith DM, Green MHL, McGregor DB, Clarke GM, Cole J, Asquith JC. 1989. Mammalian cell gene mutation assays based upon colony formation. In: Kirkland DJ, editor. Statistical Evaluation of Mutagenicity Data: UKEMS Sub-committee on Guidelines for Mutagenicity Testing, Report Part III. Cambridge, UK: Cambridge University Press. pp 66-101.
2. Balakrishnan S, Uppala PT, Rupa DS, Hasegawa L, Eastmond DA. 2002. Detection of micronuclei, cell proliferation and hyperdiploidy in bladder epithelial cells of rats treated with o-phenylphenol. Mutagen 17: 89-93.
3. Boobis A, Cohen S, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D, Farland W. 2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36: 781-792.
4. Boobis AR, Daston GP, Preston RJ, Olin SS. 2009. Application of key events analysis to chemical carcinogens and noncarcinogens. Crit Rev Food Sci Nutr 49: 690-707.
5. Brink A, Richter I, Lutz U, Wanek P, Stopper H, Lutz WK. 2009. Biological significance of DNA adducts: Comparison of increments over background for various biomarkers of genotoxicity in L5178Y tk+/- mouse lymphoma cells treated with hydrogen peroxide and cumene hydroperoxide. Mutat Res 678: 123-128.
6. Bryce SM, Bemis JC, Dertinger SD. 2008. In vivo mutation assay based on the endogenous Pig-a locus. Environ Mol Mutagen 49: 256-264.
7. Collins JE, Ellis PC, White AT, Booth AE, Moore CE, Burman M, Rees RW, Lynch AM. 2008. Evaluation of the Litron in vitro microflow kit for the flow cytometric enumeration of micronuclei (MN) in mammalian cells. Mutat Res 654: 76-81.
8. Counts JL, Goodman JI. 1995. Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: Dose influences mechanism. Regul Toxicol Pharmacol 21: 418-421.
9. Doak SH, Jenkins GJ, Johnson GE, Quick E, Parry EM, Parry JM. 2007. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. Cancer Res 67: 3904-3911.
10. Dragsted LO, Daneshvar B, Vogel U, Autrup, H.N, Wallin H, Risom L, Møller P, Mølck AM, Hansen M, Poulsen HE, Loft S. 2002. A sucrose-rich diet induces mutations in the rat colon. Cancer Res 62: 4339-4345.
11. Galloway SM, Deasy DA, Bean CL, Kraynak AR, Armstrong MJ, Bradley MO. 1987. Effects of high osmotic strength on chromosome aberrations, sister-chromatid exchanges and DNA strand breaks, and the relation to toxicity. Mutat Res 189: 15-25.
12. Gehring PJ, Blau GE. 1978. Mechanisms of carcinogenesis: Dose-response. J Environ Pathol Toxicol 1: 163-179.
13. Gocke E, Müller L. 2009. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS, ENU. Mutat Res 678: 95-100.
14. Gocke E, Wall M. 2009. In vivo genotoxicity of EMS: Statistical assessment of the dose response curves. Toxicol Lett 190: 298-302.
15. Jarabek AM, Pottenger LH, Andrews LS, Casciano D, Embry MR, Kim JH, Preston RJ, Reddy MV, Schoeny R, Shuker D, Skare J, Swenberg J, Williams GM, Zeiger E. 2009. Creating context for the use of DNA adduct data in cancer risk assessment. I. Data organization. Crit Rev Toxicol 39: 659-678.
16. Jenkins GJS, Doak SH, Johnson GE, Quick E, Waters EM, Parry JM. 2005. Do dose response thresholds exist for genotoxic alkylating agents? Mutagen 20: 389-398.
17. Johnson G, Doak SH, Griffiths SM, Quick EL, Skibinski DOF, Zaïr ZM, Jenkins GJ. 2009. Non-linear dose-response of DNA-reactive genotoxins: Recommendations for analysis. Mutat Res 678: 95-100.
18. Julien E, Boobis AR, Olin SS, ILSI Research Foundation Threshold Working Group. 2009. The key events dose-response framework: A cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. Crit Rev Food Sci Nutr 49: 682-689.
19. Kirkland D, Aardema M, Henderson L, Muller L. 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat Res 584: 1-256.
20. Kirsch-Volders M, Aardema M, Elhajouji A. 2000. Concepts of thresholds in mutagenesis and carcinogenesis. Mutat Res 464: 3-11.
21. Lutz WK. 1998. Dose-response relationships in chemical carcinogenesis, superposition of different mechanisms of activation, resulting in linear-nonlinear curves, practical thresholds, J-Shapes. Mutat Res 405: 117-124.
22. Lutz WK, Lutz RW. 2009. Statistical model to estimate a threshold dose and its confidence limits for the analysis of sublinear dose-response relationships, exemplified for mutagenicity data. Mutat Res 678: 118-122.
23. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE. 2003. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33: 591-653.
24. Parsons BL, Beland FA, Von Tungeln LS, Delongchamp RR, Fu PP, Heflich RH. 2005. Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver DNA correlate with potential for liver tumor development. Mol Carcinog 42: 193-201.
25. Parsons BL, Marchant-Miros KE, Delongchamp RR, Verkler TL, Patterson TA, McKinzie PB, Kim LT. 2010. ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. Cancer Invest 28: 364-375.
26. Phonethepswath S, Bryce SM, Bemis JC, Dertinger SD. 2008. Erythrocyte-based Pig-a gene mutation assay: Demonstration of cross-species potential. Mutat Res 657: 122-126.
27. Phonethepswath S, Franklin D, Torous DK, Bryce SM, Bemis JC, Raja S, Avlasevich S, Weller P, Hyrien O, Palis J, Macgregor JT, Dertinger SD. 2010. Pig-a mutation: Kinetics in rat erythrocytes following exposure to five prototypical mutagens. Toxicol Sci 114: 59-70.
28. Pottenger LH, Gollapudi BB. 2009. A case for a new paradigm in genetic toxicology testing. Mutat Res 678: 148-151.
29. Pottenger LH, Bus JS, Gollapudi BB. 2007. Genetic toxicity assessment: Employing the best science for human safety evaluation. VI. When salt and sugar and vegetables are positive, how can genotoxicity data serve to inform risk assessment? Toxicol Sci 98: 327-331.
30. Pottenger LH, Schisler MR, Zhang F, Bartels MJ, Fontaine D, McFadden LG, Gollapudi BB. 2009. Dose-response and operational thresholds/NOAELs for in vitro mutagenic effects from DNA-reactive mutagens, MMS and MNU. Mutat Res 678: 138-147.
31. Seidel SD, Sparrow BR, Kan HL, Stott WT, Schisler MR, Linscombe VA, Gollapudi BB. 2004. Profiles of gene expression changes in L5178Y mouse lymphoma cells treated with methyl methanesulfonate and sodium chloride. Mutagen 19: 195-201.
32. Slikker WJr, Andersen ME, Bogdanffy MS, Bus JS, Cohen SD, Conolly RB, David RM, Doerrer NG, Dorman DC, Gaylor DW, Hattis D, Rogers JM, Setzer RW, Swenberg JA, Wallace K. 2004a. Dose-dependent transitions in mechanisms of toxicity. Toxicol Appl Pharmacol 201: 203-225.
33. Slikker WJr, Andersen ME, Bogdanffy MS, Bus JS, Cohen SD, Conolly RB, David RM, Doerrer NG, Dorman DC, Gaylor, DW, Hattis D, Rogers JM, Setzer RW, Swenberg JA, Wallace K. 2004b. Dose-dependent transitions in mechanisms of toxicity: Case studies. Toxicol Appl Pharmacol 201: 226-294.
34. Swenberg JA, Fryar-Tita E, Jeong Y-C, Boysen G, Starr T, Walker VE, Albertini RJ. 2008. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. Chem Res Toxicol 21: 253-265.
35. Thybaud V, Aardema M, Casciano D, Dellarco V, Embry MR, Gollapudi BB, Hayashi M, Holsapple MP, Jacobson-Kram D, Kasper P, MacGregor JT, Rees R. 2007. Relevance and follow-up of positive results in in vitro genetic toxicity assays: An ILSI-HESI initiative. Mutat Res 633: 67-79.
36. U.S. Environmental Protection Agency (USEPA) Guidelines for Carcinogen Risk Assessment. 2005. EPA/630/P-03/001B. Risk Assessment Forum. Washington, D.C: USEPA.
37. Verkler TL, Couch LH, Howard PC, Parsons BL. 2005. Quantifying levels of p53 mutation in mouse skin tumors. Environ Mol Mutagen 45: 427-434.
38. Winer BJ. 1971. Statistical Principles in Experimental Design (2nd Edition). McGraw-Hill, New York.